Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Degarelix
Drug ID BADD_D00599
Description Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH) which ultimately causes testosterone suppression. Reduction in testosterone is important in treating men with advanced prostate cancer. Chemically, it is a synthetic linear decapeptide amide with seven unnatural amino acids, five of which are D-amino acids. FDA approved on December 24, 2008.
Indications and Usage Degaralix is used for the management of advanced prostate cancer.
Marketing Status approved
ATC Code L02BX02
DrugBank ID DB06699
KEGG ID D08901
MeSH ID C431566
PubChem ID 16136245
TTD Drug ID D0Y7KH
NDC Product Code 55566-8403; 59651-477; 55566-8303
UNII SX0XJI3A11
Synonyms acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide | uglypeptide1 | Ac-2Nal-4Cpa-3Pal-Ser-4Aph(hydroorotyl)-4Aph(carbamoyl)-Leu-ILys-pro-Ala-NH2 | Firmagon | degarelix | degarelix acetate | Gonax | FE 200486 | FE200486 | FE-200486
Chemical Information
Molecular Formula C82H103ClN18O16
CAS Registry Number 214766-78-6
SMILES CC(C)CC(C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(=O)N)NC(=O)C(CC2=CC=C(C=C2)NC (=O)N)NC(=O)C(CC3=CC=C(C=C3)NC(=O)C4CC(=O)NC(=O)N4)NC(=O)C(CO)NC(=O)C(CC5=CN=CC= C5)NC(=O)C(CC6=CC=C(C=C6)Cl)NC(=O)C(CC7=CC8=CC=CC=C8C=C7)NC(=O)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Osteopenia15.02.03.003; 14.04.04.004--Not Available
General physical health deterioration08.01.03.018--Not Available
Bone density decreased13.16.01.001--Not Available
Balance disorder08.01.03.081; 17.02.02.007--Not Available
Musculoskeletal chest pain22.09.01.001; 15.03.04.012--
Deep vein thrombosis24.01.02.003--Not Available
Malignant neoplasm progression16.16.01.005--Not Available
Injection site discolouration23.03.03.046; 12.07.03.038; 08.02.03.038--Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Lymphatic disorder01.09.01.003--Not Available
Musculoskeletal stiffness15.03.05.027--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Injection site swelling12.07.03.018; 08.02.03.017--Not Available
Nodule08.03.05.002--Not Available
Injection site discomfort12.07.03.019; 08.02.03.018--Not Available
Transaminases increased13.03.04.036--Not Available
Electrocardiogram U-wave abnormality13.14.05.028--Not Available
Pulmonary mass22.02.07.004--Not Available
Injection site nodule23.07.04.009; 12.07.03.034; 08.02.03.034--Not Available
Lung neoplasm malignant22.08.01.001; 16.19.02.001--Not Available
Disturbance in sexual arousal19.08.04.003--Not Available
Angiopathy24.03.02.007--Not Available
Blood alkaline phosphatase increased13.04.02.004--
Induration08.01.03.020--Not Available
Hot flush24.03.01.005; 21.02.02.001; 08.01.03.027--
Prostate cancer16.25.01.001; 21.04.02.002--Not Available
Adverse event08.06.01.010--Not Available
Brain neoplasm16.30.01.003; 17.20.01.003--Not Available
Breast disorder21.05.04.004--Not Available
Cardiac disorder02.11.01.003--Not Available
The 6th Page    First    Pre   6 7    Next   Last    Total 7 Pages